



## Bamlanivimab

Revised: November 15, 2023.

CASRN: 2423943-37-5

## Drug Levels and Effects

### Summary of Use during Lactation

The US FDA withdrew emergency-use authorization of bamlanivimab and etesevimab in June of 2021 because of a lack of efficacy against COVID-19 variants. Bamlanivimab is a monoclonal antibody given together with etesevimab. Both are directed against the SARS-CoV-2 virus that causes COVID-19. No information is available on the clinical use of bamlanivimab during breastfeeding. Because bamlanivimab is a large protein molecule with a molecular weight of 146,000 Da the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Until more data become available, bamlanivimab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

### Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

### Alternate Drugs to Consider

Nirmatrelvir, Remdesevir

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## References

1. Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. *Reprod Breed* 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003
2. Anderson PO. Monoclonal antibodies during breastfeeding. *Breastfeed Med* 2021;16:591-3. PubMed PMID: 33956488.

## Substance Identification

### Substance Name

Bamlanivimab

### CAS Registry Number

2423943-37-5

### Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Antibodies, Viral

Antiviral Agents